{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/hgh-fragment-176-191\/","title":{"rendered":"Fragment HGH 176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que le fragment HGH 176-191 ?<\/h3>\n<p style=\"margin: 0;\"><strong>Fragment HGH 176-191<\/strong> est un peptide synth\u00e9tique de 16 acides amin\u00e9s correspondant aux r\u00e9sidus C-terminaux 176\u2013191 de <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">l'hormone de croissance humaine<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7 (Fragment HGH 176-191 ; distinct de l'AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817.06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 acides amin\u00e9s ; positions 176\u2013191 de l'hormone de croissance humaine native, conservant le pont disulfure Cys182\u2013Cys189 de la mol\u00e9cule parente)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que le fragment HGH 176-191 ?<\/h2>\n<p><strong>Fragment HGH 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. Le fragment HGH 176-191 est structurellement et pharmacologiquement <strong>distinct de l'AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> page produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Activit\u00e9 lipolytique sans liaison au r\u00e9cepteur GH<\/h2>\n<p>Ce qui rend le fragment HGH 176-191 m\u00e9canistiquement distinctif est la <strong>dissociation de la lipolyse de la signalisation de l'axe de croissance<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>Absence de liaison au r\u00e9cepteur de GH<\/strong> \u2014 La surface de liaison au r\u00e9cepteur de GH de l'HGH native est contenue dans la partie N-terminale de la mol\u00e9cule (r\u00e9gion des r\u00e9sidus 1\u2013120), et non dans le fragment C-terminal 176\u2013191. Par cons\u00e9quent, le fragment HGH 176-191 ne se lie PAS au r\u00e9cepteur de l'hormone de croissance (GHR), n'active PAS la signalisation JAK2\/STAT5, n'induit PAS la production h\u00e9patique d'IGF-1 et ne produit AUCUN des effets promoteurs de croissance, stimulateurs de chondrocytes ou contre-r\u00e9gulateurs de l'insuline de la mol\u00e9cule parente. C'est la propri\u00e9t\u00e9 pharmacologique n\u00e9gative d\u00e9terminante et la base de son utilit\u00e9 comme outil isolant l'axe lipolytique. <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>\u2014 Des recherches publi\u00e9es ont document\u00e9 que le fragment HGH 176-191 conserve l'activit\u00e9 mobilisatrice de graisses de l'HGH compl\u00e8te au niveau des adipocytes. La cible mol\u00e9culaire exacte sous-jacente \u00e0 l'effet lipolytique reste une question de recherche active ; les m\u00e9canismes propos\u00e9s incluent une action directe sur les r\u00e9cepteurs adr\u00e9nergiques b\u00eata-3 des adipocytes, la modulation de la lipase hormono-sensible et des modifications de la cin\u00e9tique d'oxydation des acides gras. Le signal lipolytique est pr\u00e9f\u00e9rentiellement observ\u00e9 dans les d\u00e9p\u00f4ts de tissu adipeux visc\u00e9ral dans certaines recherches publi\u00e9es sur les rongeurs, parall\u00e8lement mais m\u00e9canistiquement distinct du<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>\u2014 En plus de stimuler la mobilisation des graisses, le fragment HGH 176-191 supprime l'expression des g\u00e8nes lipog\u00e9niques dans les mod\u00e8les de recherche sur les adipocytes \u2014 r\u00e9duisant le taux de nouveau stockage des graisses parall\u00e8lement \u00e0 l'augmentation de la mobilisation des graisses. Les deux effets produisent un signal de bilan lipidique net n\u00e9gatif dans le tissu adipeux.<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Pharmacologie de la lipolyse des adipocytes<\/strong> \u2014 caract\u00e9risation du m\u00e9canisme lipolytique isol\u00e9, \u00e9tudes d'interaction avec le r\u00e9cepteur adr\u00e9nergique b\u00eata-3, activation de la lipase hormono-sensible, cin\u00e9tique de mobilisation des acides gras<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 dissection m\u00e9canistique des domaines d'activit\u00e9 de promotion de la croissance vs lipolytique au sein de l'HGH native ; le fragment 176-191 de l'HGH comme outil canonique \u201c lipolyse uniquement \u201d, avec <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> comme comparateur d'activit\u00e9 compl\u00e8te<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 diff\u00e9renciation des adipocytes, formation des gouttelettes lipidiques, interactions des voies PPAR\u03b3 et SREBP-1<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 comparaisons directes avec <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 \u00e9valuation comparative contre <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> (HGH parente compl\u00e8te), <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> (analogue de la GHRH du tissu adipeux visc\u00e9ral), et <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295<\/a> (stimulateurs de l'axe GHRH).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> comme le peptide parent complet, <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> pour l'approche par l'axe GHRH de l'adiposit\u00e9 visc\u00e9rale, et <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles \u00e0 cycles prolong\u00e9s, co\u00fbt par mg le plus bas, \u00e9tudes multi-cohortes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>Comparaison \u2014 Fragment HGH 176-191 vs HGH 191AA<\/h2>\n<p>Le fragment HGH 176-191 et <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragment HGH 176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA (forme compl\u00e8te)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 acides amin\u00e9s (~1,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 acides amin\u00e9s (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Fixation au r\u00e9cepteur de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Non (le domaine de fixation est N-terminal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui (mol\u00e9cule pleine longueur)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Induction d'IGF-1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Induction h\u00e9patique substantielle<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Activit\u00e9 lipolytique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui (conserv\u00e9e)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui (activit\u00e9 parentale pleine longueur)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effets promoteurs de croissance<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Substantiels (peptide anabolique canonique)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet insulinor\u00e9gulateur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Non<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Oui (r\u00e9sistance \u00e0 l'insuline transitoire)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie plasmatique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 heures<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Utilisation clinique approuv\u00e9e<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aucun<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indications multiples (Genotropin, Humatrope, etc.)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\u2013500\u00a0mcg, 1\u20133 fois par jour<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138\u00a0UI par administration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138\u00a0\u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220\u00a0\u00b0C. Le fragment 176-191 de l'HGH lyophilis\u00e9 est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220\u00a0\u00b0C jusqu'\u00e0 36 mois. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. Comme d'autres peptides pont\u00e9s par des disulfures, l'activit\u00e9 du fragment d\u00e9pend de la liaison intacte Cys182\u2013Cys189 (num\u00e9rotation Cys7\u2013Cys14 du fragment) \u2014 toute manipulation perturbant le disulfure d\u00e9gradera l'activit\u00e9. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon de peptide (pas directement sur le g\u00e2teau lyophilis\u00e9). Pour un flacon de 5\u00a0mg, 2,0\u00a0mL d'eau bact\u00e9riostatique donnent une concentration de travail de 2,5\u00a0mg\/mL \u2014 0,04\u00a0mL d\u00e9livre 100\u00a0mcg ; 0,1\u00a0mL d\u00e9livre 250\u00a0mcg ; 0,2\u00a0mL d\u00e9livre 500\u00a0mcg. Agiter doucement \u2014 ne pas <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore. <strong>Apr\u00e8s reconstitution :<\/strong> conserver au r\u00e9frig\u00e9rateur \u00e0 2\u20138\u00a0\u00b0C et utiliser dans les 30 jours pour une stabilit\u00e9 optimale. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent l'int\u00e9grit\u00e9 du peptide et peuvent perturber la liaison disulfure. Jeter tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi le fragment 176-191 de l'HGH diff\u00e8re-t-il de l'HGH 191AA ?<\/h3>\n<p>Le fragment 176-191 de l'HGH ne contient que 16 acides amin\u00e9s \u2014 la partie C-terminale de l'HGH enti\u00e8re de 191 acides amin\u00e9s. Le fragment ne poss\u00e8de pas le domaine de liaison au r\u00e9cepteur de GH (qui se trouve dans la partie N-terminale de la mol\u00e9cule parente), donc il ne se lie PAS au GHR, n'induit PAS l'IGF-1 et ne produit AUCUN des effets de promotion de la croissance ou insulinor\u00e9gulateurs de l'HGH enti\u00e8re. Il ne conserve que l'activit\u00e9 lipolytique et antilipog\u00e9nique. <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> est la mol\u00e9cule parente compl\u00e8te pr\u00e9sentant \u00e0 la fois une activit\u00e9 lipolytique ET une activit\u00e9 sur l'axe de croissance. <\/p>\n<h3>En quoi le fragment HGH 176-191 diff\u00e8re-t-il de l'AOD9604 ?<\/h3>\n<p>Ce sont <strong>des compos\u00e9s distincts<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>Le fragment HGH 176-191 est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>Comment le fragment HGH 176-191 doit-il \u00eatre stock\u00e9 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide et peuvent perturber le pont disulfure essentiel Cys182\u2013Cys189. Prot\u00e9ger de la lumi\u00e8re directe \u00e0 tout moment. <\/p>\n<h3>Comment reconstituer le fragment HGH 176-191 ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> secouez le flacon \u2014 une agitation vigoureuse peut perturber la liaison disulfure. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 2,0 mL de diluant, la concentration de travail est de 2,5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi le fragment HGH 176-191 n'affecte-t-il pas l'IGF-1 ?<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>D'o\u00f9 provient l'activit\u00e9 lipolytique si ce n'est pas de la liaison au r\u00e9cepteur de la GH ?<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>Quelle est la demi-vie du fragment 176-191 de l'HGH ?<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>Puis-je commander le fragment 176-191 de l'HGH pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le fragment HGH 176-191 dans le monde entier depuis notre r\u00e9seau d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Hormone de croissance humaine recombinante pleine longueur \u2014 la mol\u00e9cule parente de ce fragment<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/fr\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/fr\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s de l'axe de croissance incluant <a href=\"https:\/\/medsbase.com\/fr\/hgh-191aa\/\">HGH 191AA<\/a> (HGH parente compl\u00e8te), <a href=\"https:\/\/medsbase.com\/fr\/tesamorelin\/\">Tesamorelin<\/a> (analogue de GHRH pour l'adiposit\u00e9 visc\u00e9rale), <a href=\"https:\/\/medsbase.com\/fr\/sermorelin\/\">Sermorelin<\/a> et <a href=\"https:\/\/medsbase.com\/fr\/cjc-1295-with-dac\/\">CJC-1295 avec DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragment C-terminal de 16-aa de l'hormone de croissance humaine<br \/>\n\u2705 Conserve l'activit\u00e9 lipolytique, sans liaison au r\u00e9cepteur GH<br \/>\n\u2705 Pas d'induction d'IGF-1 ni d'effets promoteurs de croissance<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 Puret\u00e9 \u226599% en HPLC, COA sur demande<\/p>\n<p><strong>Fragment HGH 176-191<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}